WHAT ARE CLINICAL TRIALS

Clinical trials are voluntary research studies conducted in people designed to find:

- **Potential** new medicines
- **Improved** versions of medicines already being used
- **New** uses for medicines already being used

PARTICIPATION WITH A PURPOSE

All clinical studies are required to be reviewed by an independent review board or ethics committee, who helps ensure that the study is safe and appropriately conducted, and the rights and safety of study participants are protected. Clinical trials are conducted by experienced and trained medical professionals, with patient safety and health closely monitored and of top priority.

NOW ENROLLING

This guide is not a replacement for the Informed Consent Form or for a discussion of your questions with the study doctor. Participation in any clinical study is completely voluntary.



IS THE SYNERGY-101 STUDY (STK-012-101) RIGHT FOR ME?

The **SYNERGY-101 study** is a Phase 2 clinical research study for adults who have a diagnosis of advanced non-small cell lung cancer (NSCLC) and have not received any treatment for NSCLC. The study will test how well an investigational new drug, STK-012, works in combination with pembrolizumab, pemetrexed, and carboplatin, a standard treatment for NSCLC . “Investigational” means the drug has not been approved by any authority that regulates new medicines, including the FDA.

CONTACT YOUR TREATING PHYSICIAN FOR MORE INFORMATION

Additional information is available on **www.ClinicalTrials.gov** (ID: NCT05098132)

Synthekine

HOW STK-012 WORKS

STK-012 is an investigational new drug being studied by Synthekine, the sponsor of this study. STK-012 is a modified (changed in the laboratory) form of a protein called interleukin-2 (IL-2) that is normally made by your immune system. STK-012 may help activate your immune system to attack cancer cells.

PATIENT JOURNEY

If you participate in this study, you will undergo the following activities:

01

INFORMED CONSENT FORM (ICF) REVIEW AND SIGNATURE:

The ICF contains information about the study including its goals, duration, benefits, risks, tests, and procedures.

02

SCREENING PERIOD:

You will complete tests to confirm you can join the study. These include review of your medical history and medications, a physical exam, blood and urine tests, heart tests, and CT/MRI scans.

Your doctor will review the test results and let you know if you are eligible to join the study.

03

TREATMENT PERIOD:

You will be randomly assigned to 1 of 3 possible treatment groups. All groups will receive standard treatment with pembrolizumab, pemetrexed, and carboplatin given through the vein (intravenously) every 3 weeks (Q3W). Two groups will have STK-012 added to this standard treatment, which means you will have a 2 in 3 chance of receiving STK-012. STK-012 will be given as an injection under the skin (subcutaneously) Q3W.

Treatment groups:

- Pembrolizumab, pemetrexed, and carboplatin alone
- Pembrolizumab, pemetrexed, and carboplatin, plus STK-012 at one dose
- Pembrolizumab, pemetrexed, and carboplatin, plus STK-012 at a different dose

You will receive treatment for as long as you are benefiting from it. The study doctor may interrupt or stop your dosing if side effects occur. While receiving treatment, study tests (like those at Screening) will be performed on a regular basis to monitor you for potential benefits or side effects from study treatment.

04

FOLLOW-UP PERIOD:

If you stop taking treatment, the study team will ask you to complete additional study tests to monitor you for potential benefits or side effects from study treatment. The study team will explain which tests you will receive and the schedule.